{"id":"ly2216684-edivoxetine","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edivoxetine works by blocking the reuptake of norepinephrine at the presynaptic neuron, thereby increasing norepinephrine concentration in the synaptic cleft. This mechanism is thought to enhance attention, focus, and executive function. The drug was developed for attention-deficit/hyperactivity disorder (ADHD) and other conditions where noradrenergic dysfunction plays a role.","oneSentence":"LY2216684 (edivoxetine) is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:53.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT00965419","phase":"PHASE2, PHASE3","title":"A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":267},{"nctId":"NCT01380691","phase":"PHASE1","title":"A Study of LY2216684 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-06","conditions":"Major Depressive Disorder","enrollment":28},{"nctId":"NCT01370499","phase":"PHASE3","title":"A Study of LY2216684 in Participants With Major Depression Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":"Major Depressive Disorder","enrollment":288},{"nctId":"NCT01241435","phase":"PHASE1","title":"A Study of LY2216684 in Participants With Impaired Hepatic Function","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Depressive Disorder, Major","enrollment":36},{"nctId":"NCT00420004","phase":"PHASE2","title":"A Study for Participants With Major Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-12","conditions":"Major Depressive Disorder","enrollment":469},{"nctId":"NCT01185340","phase":"PHASE3","title":"A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Major Depressive Disorder","enrollment":1056},{"nctId":"NCT01187407","phase":"PHASE3","title":"A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Major Depressive Disorder (MDD)","enrollment":1480},{"nctId":"NCT01299272","phase":"PHASE3","title":"A Study in Prevention of Re-emergence of Depression Symptoms","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-05","conditions":"Major Depressive Disorder","enrollment":1249},{"nctId":"NCT01173601","phase":"PHASE3","title":"A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Major Depressive Disorder","enrollment":1416},{"nctId":"NCT01155661","phase":"PHASE3","title":"A Safety Study in Participants With Major Depressive Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Depressive Disorder, Major","enrollment":608},{"nctId":"NCT00922636","phase":"PHASE2, PHASE3","title":"A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-06","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY2216684","edivoxetine"],"phase":"phase_3","status":"active","brandName":"LY2216684 (edivoxetine)","genericName":"LY2216684 (edivoxetine)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY2216684 (edivoxetine) is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}